Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Capital Expenditures (2022 - 2025)

Prokidney (PROK) has disclosed Capital Expenditures for 4 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 77.45% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.2 million through Dec 2025, down 48.5% year-over-year, with the annual reading at $15.2 million for FY2025, 48.5% down from the prior year.
  • Capital Expenditures for Q4 2025 was $5.8 million at Prokidney, up from $5.2 million in the prior quarter.
  • The five-year high for Capital Expenditures was $27.9 million in Q3 2023, with the low at $306000.0 in Q4 2022.
  • Average Capital Expenditures over 4 years is $5.0 million, with a median of $1.4 million recorded in 2023.
  • The sharpest move saw Capital Expenditures skyrocketed 8769.52% in 2023, then crashed 91.4% in 2024.
  • Over 4 years, Capital Expenditures stood at $306000.0 in 2022, then soared by 413.73% to $1.6 million in 2023, then surged by 1522.71% to $25.5 million in 2024, then crashed by 77.45% to $5.8 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $5.8 million, $5.2 million, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.